GSA Capital Partners’s Adverum Biotechnologies ADVM Stock Holding History

GSA Capital Partners’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-12,268	Closed	-$195K	–	1448
2023 Q2	$195K	Sell	12,268 -75,700	-86%	-$796K	0.02%	1278
2023 Q1	$631K	Buy	87,968 +4,885	+6%	+$34.5K	0.06%	569
2022 Q4	$481K	Buy	83,083 +75,175	+951%	+$570K	0.06%	621
2022 Q3	$75K	Buy	+7,908	New	+$104K	0.01%	1393
2022 Q2	–	Sell	-39,559	Closed	-$518K	–	1350
2022 Q1	$518K	Sell	39,559 -12,669	-24%	-$185K	0.07%	506
2021 Q4	$919K	Buy	+52,228	New	+$1.05M	0.12%	243
2020 Q4	–	Sell	-1,166	Closed	-$120K	–	1160
2020 Q3	$120K	Buy	+1,166	New	+$175K	0.02%	1107
2020 Q1	–	Sell	-1,628	Closed	-$188K	–	1011
2019 Q4	$188K	Buy	+1,628	New	+$143K	0.02%	1273
2018 Q4	–	Sell	-1,480	Closed	-$90K	–	1305
2018 Q3	$90K	Buy	+1,480	New	+$83.1K	0.01%	1565

Other funds holding ADVM

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

SGL

Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

GSA Capital Partners's ADVM Position: Q3 2023 in Review

GSA Capital Partners sold out of Adverum Biotechnologies (ADVM) in Q3 2023, closing a stake of 12,268 shares — an estimated $195K sold.

GSA Capital Partners first reported a position in ADVM in Q3 2018 and held it in 9 quarters. The position peaked at $919K in Q4 2021. 59 funds tracked by Wall St. Rank hold ADVM as of Q3 2023.

GSA Capital Partners reported no remaining Adverum Biotechnologies position as of Q3 2023 after selling out during the quarter.
GSA Capital Partners sold 12,268 Adverum Biotechnologies shares in Q3 2023, an estimated $195K.
GSA Capital Partners first reported a position in Adverum Biotechnologies in Q3 2018 and held it in 9 quarters.
GSA Capital Partners's Adverum Biotechnologies position peaked at $919K in Q4 2021.
59 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2023.

Based on GSA Capital Partners's 13F filing for Q3 2023, filed 15 Nov 2023.